Clearmind Medicine Inc. announced that it has filed a patent application with United States Patent and Trademark Office (USPTO) for the use of 3-methylmethcathinone (with the chemical name 2-(methylamino)-1-(3-methylphenyl)-1-propanon), to prevent and/or treat eating disorders either alone or in conjunction with Palmitoylethanolamide.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.1 USD | +0.92% | -3.51% | -60.85% |
1st Jan change | Capi. | |
---|---|---|
-60.85% | 3.56M | |
+45.62% | 56.65B | |
-6.88% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.59% | 26.75B | |
-21.34% | 19.03B | |
+0.96% | 12.28B | |
+24.15% | 12.26B | |
+27.25% | 12.04B |
- Stock Market
- Equities
- CMND Stock
- News Clearmind Medicine Inc.
- Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders